Cargando…

PIM Kinases as Potential Therapeutic Targets in a Subset of Peripheral T Cell Lymphoma Cases

Currently, there is no efficient therapy for patients with peripheral T cell lymphoma (PTCL). The Proviral Integration site of Moloney murine leukemia virus (PIM) kinases are important mediators of cell survival. We aimed to determine the therapeutic value of PIM kinases because they are overexpress...

Descripción completa

Detalles Bibliográficos
Autores principales: Martín-Sánchez, Esperanza, Odqvist, Lina, Rodríguez-Pinilla, Socorro M., Sánchez-Beato, Margarita, Roncador, Giovanna, Domínguez-González, Beatriz, Blanco-Aparicio, Carmen, García Collazo, Ana M., Cantalapiedra, Esther González, Fernández, Joaquín Pastor, del Olmo, Soraya Curiel, Pisonero, Helena, Madureira, Rebeca, Almaraz, Carmen, Mollejo, Manuela, Alves, F. Javier, Menárguez, Javier, González-Palacios, Fernando, Rodríguez-Peralto, José Luis, Ortiz-Romero, Pablo L., Real, Francisco X., García, Juan F., Bischoff, James R., Piris, Miguel A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4227704/
https://www.ncbi.nlm.nih.gov/pubmed/25386922
http://dx.doi.org/10.1371/journal.pone.0112148
_version_ 1782343856794107904
author Martín-Sánchez, Esperanza
Odqvist, Lina
Rodríguez-Pinilla, Socorro M.
Sánchez-Beato, Margarita
Roncador, Giovanna
Domínguez-González, Beatriz
Blanco-Aparicio, Carmen
García Collazo, Ana M.
Cantalapiedra, Esther González
Fernández, Joaquín Pastor
del Olmo, Soraya Curiel
Pisonero, Helena
Madureira, Rebeca
Almaraz, Carmen
Mollejo, Manuela
Alves, F. Javier
Menárguez, Javier
González-Palacios, Fernando
Rodríguez-Peralto, José Luis
Ortiz-Romero, Pablo L.
Real, Francisco X.
García, Juan F.
Bischoff, James R.
Piris, Miguel A.
author_facet Martín-Sánchez, Esperanza
Odqvist, Lina
Rodríguez-Pinilla, Socorro M.
Sánchez-Beato, Margarita
Roncador, Giovanna
Domínguez-González, Beatriz
Blanco-Aparicio, Carmen
García Collazo, Ana M.
Cantalapiedra, Esther González
Fernández, Joaquín Pastor
del Olmo, Soraya Curiel
Pisonero, Helena
Madureira, Rebeca
Almaraz, Carmen
Mollejo, Manuela
Alves, F. Javier
Menárguez, Javier
González-Palacios, Fernando
Rodríguez-Peralto, José Luis
Ortiz-Romero, Pablo L.
Real, Francisco X.
García, Juan F.
Bischoff, James R.
Piris, Miguel A.
author_sort Martín-Sánchez, Esperanza
collection PubMed
description Currently, there is no efficient therapy for patients with peripheral T cell lymphoma (PTCL). The Proviral Integration site of Moloney murine leukemia virus (PIM) kinases are important mediators of cell survival. We aimed to determine the therapeutic value of PIM kinases because they are overexpressed in PTCL patients, T cell lines and primary tumoral T cells. PIM kinases were inhibited genetically (using small interfering and short hairpin RNAs) and pharmacologically (mainly with the pan-PIM inhibitor (PIMi) ETP-39010) in a panel of 8 PTCL cell lines. Effects on cell viability, apoptosis, cell cycle, key proteins and gene expression were evaluated. Individual inhibition of each of the PIM genes did not affect PTCL cell survival, partially because of a compensatory mechanism among the three PIM genes. In contrast, pharmacological inhibition of all PIM kinases strongly induced apoptosis in all PTCL cell lines, without cell cycle arrest, in part through the induction of DNA damage. Therefore, pan-PIMi synergized with Cisplatin. Importantly, pharmacological inhibition of PIM reduced primary tumoral T cell viability without affecting normal T cells ex vivo. Since anaplastic large cell lymphoma (ALK+ ALCL) cell lines were the most sensitive to the pan-PIMi, we tested the simultaneous inhibition of ALK and PIM kinases and found a strong synergistic effect in ALK+ ALCL cell lines. Our findings suggest that PIM kinase inhibition could be of therapeutic value in a subset of PTCL, especially when combined with ALK inhibitors, and might be clinically beneficial in ALK+ ALCL.
format Online
Article
Text
id pubmed-4227704
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-42277042014-11-18 PIM Kinases as Potential Therapeutic Targets in a Subset of Peripheral T Cell Lymphoma Cases Martín-Sánchez, Esperanza Odqvist, Lina Rodríguez-Pinilla, Socorro M. Sánchez-Beato, Margarita Roncador, Giovanna Domínguez-González, Beatriz Blanco-Aparicio, Carmen García Collazo, Ana M. Cantalapiedra, Esther González Fernández, Joaquín Pastor del Olmo, Soraya Curiel Pisonero, Helena Madureira, Rebeca Almaraz, Carmen Mollejo, Manuela Alves, F. Javier Menárguez, Javier González-Palacios, Fernando Rodríguez-Peralto, José Luis Ortiz-Romero, Pablo L. Real, Francisco X. García, Juan F. Bischoff, James R. Piris, Miguel A. PLoS One Research Article Currently, there is no efficient therapy for patients with peripheral T cell lymphoma (PTCL). The Proviral Integration site of Moloney murine leukemia virus (PIM) kinases are important mediators of cell survival. We aimed to determine the therapeutic value of PIM kinases because they are overexpressed in PTCL patients, T cell lines and primary tumoral T cells. PIM kinases were inhibited genetically (using small interfering and short hairpin RNAs) and pharmacologically (mainly with the pan-PIM inhibitor (PIMi) ETP-39010) in a panel of 8 PTCL cell lines. Effects on cell viability, apoptosis, cell cycle, key proteins and gene expression were evaluated. Individual inhibition of each of the PIM genes did not affect PTCL cell survival, partially because of a compensatory mechanism among the three PIM genes. In contrast, pharmacological inhibition of all PIM kinases strongly induced apoptosis in all PTCL cell lines, without cell cycle arrest, in part through the induction of DNA damage. Therefore, pan-PIMi synergized with Cisplatin. Importantly, pharmacological inhibition of PIM reduced primary tumoral T cell viability without affecting normal T cells ex vivo. Since anaplastic large cell lymphoma (ALK+ ALCL) cell lines were the most sensitive to the pan-PIMi, we tested the simultaneous inhibition of ALK and PIM kinases and found a strong synergistic effect in ALK+ ALCL cell lines. Our findings suggest that PIM kinase inhibition could be of therapeutic value in a subset of PTCL, especially when combined with ALK inhibitors, and might be clinically beneficial in ALK+ ALCL. Public Library of Science 2014-11-11 /pmc/articles/PMC4227704/ /pubmed/25386922 http://dx.doi.org/10.1371/journal.pone.0112148 Text en © 2014 Martín-Sánchez et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Martín-Sánchez, Esperanza
Odqvist, Lina
Rodríguez-Pinilla, Socorro M.
Sánchez-Beato, Margarita
Roncador, Giovanna
Domínguez-González, Beatriz
Blanco-Aparicio, Carmen
García Collazo, Ana M.
Cantalapiedra, Esther González
Fernández, Joaquín Pastor
del Olmo, Soraya Curiel
Pisonero, Helena
Madureira, Rebeca
Almaraz, Carmen
Mollejo, Manuela
Alves, F. Javier
Menárguez, Javier
González-Palacios, Fernando
Rodríguez-Peralto, José Luis
Ortiz-Romero, Pablo L.
Real, Francisco X.
García, Juan F.
Bischoff, James R.
Piris, Miguel A.
PIM Kinases as Potential Therapeutic Targets in a Subset of Peripheral T Cell Lymphoma Cases
title PIM Kinases as Potential Therapeutic Targets in a Subset of Peripheral T Cell Lymphoma Cases
title_full PIM Kinases as Potential Therapeutic Targets in a Subset of Peripheral T Cell Lymphoma Cases
title_fullStr PIM Kinases as Potential Therapeutic Targets in a Subset of Peripheral T Cell Lymphoma Cases
title_full_unstemmed PIM Kinases as Potential Therapeutic Targets in a Subset of Peripheral T Cell Lymphoma Cases
title_short PIM Kinases as Potential Therapeutic Targets in a Subset of Peripheral T Cell Lymphoma Cases
title_sort pim kinases as potential therapeutic targets in a subset of peripheral t cell lymphoma cases
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4227704/
https://www.ncbi.nlm.nih.gov/pubmed/25386922
http://dx.doi.org/10.1371/journal.pone.0112148
work_keys_str_mv AT martinsanchezesperanza pimkinasesaspotentialtherapeutictargetsinasubsetofperipheraltcelllymphomacases
AT odqvistlina pimkinasesaspotentialtherapeutictargetsinasubsetofperipheraltcelllymphomacases
AT rodriguezpinillasocorrom pimkinasesaspotentialtherapeutictargetsinasubsetofperipheraltcelllymphomacases
AT sanchezbeatomargarita pimkinasesaspotentialtherapeutictargetsinasubsetofperipheraltcelllymphomacases
AT roncadorgiovanna pimkinasesaspotentialtherapeutictargetsinasubsetofperipheraltcelllymphomacases
AT dominguezgonzalezbeatriz pimkinasesaspotentialtherapeutictargetsinasubsetofperipheraltcelllymphomacases
AT blancoapariciocarmen pimkinasesaspotentialtherapeutictargetsinasubsetofperipheraltcelllymphomacases
AT garciacollazoanam pimkinasesaspotentialtherapeutictargetsinasubsetofperipheraltcelllymphomacases
AT cantalapiedraesthergonzalez pimkinasesaspotentialtherapeutictargetsinasubsetofperipheraltcelllymphomacases
AT fernandezjoaquinpastor pimkinasesaspotentialtherapeutictargetsinasubsetofperipheraltcelllymphomacases
AT delolmosorayacuriel pimkinasesaspotentialtherapeutictargetsinasubsetofperipheraltcelllymphomacases
AT pisonerohelena pimkinasesaspotentialtherapeutictargetsinasubsetofperipheraltcelllymphomacases
AT madureirarebeca pimkinasesaspotentialtherapeutictargetsinasubsetofperipheraltcelllymphomacases
AT almarazcarmen pimkinasesaspotentialtherapeutictargetsinasubsetofperipheraltcelllymphomacases
AT mollejomanuela pimkinasesaspotentialtherapeutictargetsinasubsetofperipheraltcelllymphomacases
AT alvesfjavier pimkinasesaspotentialtherapeutictargetsinasubsetofperipheraltcelllymphomacases
AT menarguezjavier pimkinasesaspotentialtherapeutictargetsinasubsetofperipheraltcelllymphomacases
AT gonzalezpalaciosfernando pimkinasesaspotentialtherapeutictargetsinasubsetofperipheraltcelllymphomacases
AT rodriguezperaltojoseluis pimkinasesaspotentialtherapeutictargetsinasubsetofperipheraltcelllymphomacases
AT ortizromeropablol pimkinasesaspotentialtherapeutictargetsinasubsetofperipheraltcelllymphomacases
AT realfranciscox pimkinasesaspotentialtherapeutictargetsinasubsetofperipheraltcelllymphomacases
AT garciajuanf pimkinasesaspotentialtherapeutictargetsinasubsetofperipheraltcelllymphomacases
AT bischoffjamesr pimkinasesaspotentialtherapeutictargetsinasubsetofperipheraltcelllymphomacases
AT pirismiguela pimkinasesaspotentialtherapeutictargetsinasubsetofperipheraltcelllymphomacases